PharmGen Science
004720
Company Profile
Business description
PharmGen Science is a Korea-based company engaged in the business divisions of pharmaceutical business, healthcare business, and other businesses. The pharmaceutical business provides Prescription drugs such as digestive medicines, over-the-counter drugs, obesity treatments, etc; the Healthcare business operates in Health functional foods, beauty products; and Other businesses include Real estate rental business. The group generates the majority of its revenue from the pharmaceutical business.
Contact
50, Yakjakgongdan 2-gil
Hyangnam-eup
Gyeonggi-do
Hwaseong-si18622
KORT: +82 221943532
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
235
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
stocks
Bapcor is paying for the sins of its past
Shares plunged over 17% after reporting disappointing results.
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,324.60 | 40.80 | 0.44% |
| CAC 40 | 8,206.07 | 31.87 | 0.39% |
| DAX 40 | 24,258.80 | 427.81 | 1.80% |
| Dow JONES (US) | 46,706.58 | 515.97 | 1.12% |
| FTSE 100 | 9,403.57 | 49.00 | 0.52% |
| HKSE | 25,858.83 | 611.73 | 2.42% |
| NASDAQ | 22,990.54 | 310.57 | 1.37% |
| Nikkei 225 | 49,185.50 | 1,603.35 | 3.37% |
| NZX 50 Index | 13,317.40 | 27.56 | -0.21% |
| S&P 500 | 6,735.13 | 71.12 | 1.07% |
| S&P/ASX 200 | 9,031.90 | 43.70 | 0.49% |
| SSE Composite Index | 3,863.89 | 24.14 | 0.63% |